Colorectal cancer is highly treatable when caught early, yet it continues to take more Black lives than any other racial group. UCLA health researchers report that Black Americans face about 20 percent higher incidence and about 30 percent higher mortality compared with white adults. How does it connect to IBD?
More people are being diagnosed with Crohn’s disease and ulcerative colitis in adulthood. These conditions already increase cancer risk, but the reason has never been fully understood.
A new 2026 study from Weill Cornell Medicine offers a clearer explanation. The research identifies a chain of immune activity that begins in the gut and reaches the bone marrow, creating conditions that can support tumor development. It is one of the most detailed looks yet at how long-standing inflammation shapes cancer risk.
Table of Contents
A Quick Look at IBD
Inflammatory bowel disease, or IBD, is the umbrella term for Crohn’s disease and ulcerative colitis. Ulcerative colitis affects the lining of the colon and rectum, creating inflammation that stays close to the surface. Crohn’s disease can involve deeper layers of the digestive tract and may affect any part of the digestive tract, from the small intestine to the large intestine. Both conditions reflect an immune system that remains active longer than it should, setting the stage for an inflammatory loop.
The Loop Inside the Gut
The Cornell team studied TL1A, a protein that rises during gut inflammation. When TL1A increases, a group of intestinal immune cells called ILC3s responds. These cells release a growth factor that travels to the bone marrow. The bone marrow then produces a surge of neutrophils, which are white blood cells that normally help fight infection.
In this situation, the neutrophils behave differently. They move into the gut and release chemicals that can damage DNA in the cells lining the colon. Damaged DNA increases the chance of pre-cancerous changes. The researchers also found that these neutrophils develop a specific gene activity pattern that supports tumor growth. This pattern was present in tissue samples from people with IBD and was less pronounced in patients who received an experimental TL1A-blocking treatment.
Scientists can now see the connection between the gut and bone marrow as a single path, not a set of disconnected clues.
The Affect on Black Health
Black people in the U.S. continue to face higher colorectal cancer incidence and mortality than white patients, a gap driven less by biology and more by the conditions that shape access to care. Research from UCLA highlights how delayed screening, limited access to specialists, financial barriers, and uneven treatment quality all contribute to later diagnoses and worse outcomes. These same barriers show up in IBD care, where Black patients often wait longer for Crohn’s or ulcerative colitis to be recognized and treated. When inflammation goes untreated, the immune loop has more time to escalate, causing damage.
How TL1A and Neutrophils Work
TL1A is a signal that alerts the immune system. ILC3s are the cells that receive that signal. Neutrophils are the cells that respond. When this system is activated repeatedly, the response becomes more forceful. The Cornell study shows that this heightened response can harm healthy tissue and create an environment where cancer is more likely to develop.
Understanding this pathway helps clinicians identify which patients may need closer monitoring. It also helps patients understand why inflammation control is essential, even during slower periods of disease.
A New Direction for Prevention
One of the most promising findings in the study is that blocking TL1A reduced the harmful neutrophil signature. This suggests that future treatments may be able to interrupt the inflammatory loop before it leads to DNA damage. It also raises the possibility of new blood or tissue markers that can identify patients at higher risk for cancer.
This could change how IBD is monitored. Instead of relying solely on colonoscopies, one day clinicians may track specific immune patterns that reveal how inflammation behaves throughout the body.
Where This Research Leads
This research shifts how IBD is understood. It shows that inflammation involves both the gut and the bone marrow. That’s why early recognition and steady care matter so much, especially for those who have faced delayed diagnoses.
It also gives clinicians a clearer view of what is happening inside the body and why some patients face higher long-term risks. That clarity can push better decisions and open the door to tools that lower cancer risk. After decades of circling the same questions about chronic inflammation, this work finally gives the field what it has long needed: a real path forward.
Resources:
